STALICLA Completes Successful Phase 1b Trials for the First Precision Medicine in Autism Spectrum Disorder
STALICLA, a Swiss clinical stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), announced today the highly successful completion of the phase 1b trials for its lead drug candidate STP1. These clinical data clear the way for a first application of STALICLA’s precision medicine discovery platform in autism spectrum disorders.
The goal of this phase 1b, double-blind, placebo-controlled study was to evaluate the safety, tolerability, and pharmacokinetics of a two-week oral treatment with STP1 in a subgroup of patients with ASD. In addition to showing good safety and tolerability profiles, and dose-dependent target engagement, STP1 treatment resulted in positive signals in clinical markers of neurological and behavioral function, including improved processing speed and crystallized cognition composite.
Speaking about the results, Dr Craig Erickson, M.D. – lead investigator at Cincinnati Children’s Hospital said: “The electrophysiological signals from this study are remarkable and represent the strongest early trial target engagement signals our lab has seen in the autism field. The findings from this project de-risk future larger-scale study given the personalized approach employed to biologically identify specific autistic individuals who may best respond to a treatment prior to study enrollment.”
Baltazar Gomez Mancilla, STALICAL’s CMO, added: “Beyond molecular impact, we are seeing a dose-related decrease of specific abnormal electrophysiological signal in brain regions related to social interaction, working memory and processing speed that may lead to social communication improvement, which is one of the core symptoms of autism. Those results and the prospects of a personalized solution addressing ASD could be a tremendous game-changer for this subgroup of patients representing 20% of ASD population.”
STALICLA drug development relies on DEPI, the AI-driven and clinically validated biotech platform integrating comprehensive metabolomics, whole-genome sequencing, RNA sequencing and a proprietary module to pair patient biological signatures with drug candidates. Using DEPI, STALICLA already proved the clinical validity of several subgroups with neurodevelopmental disorders (Phen1, Phen2, Phen3, Phen5) and their respective tailored treatments, starting with STP1.
Speaking about next steps, Lynn Durham, STALICLA’s CEO & Founder, commented: “We are now turning our sights to the next stage of our growth with some major milestones. First, a multicenter bio sampling study for the enrollment of STP1 phase 2, which should allow us to gather the most comprehensive clinical and multi-omics data set to date in the ASD space. Then, the continuation of STP1 phase 2, increasing treatment duration and dose level, adding a working memory test, and further refining phase 1b's strong findings. Finally, our other milestones will include phase 2 trials for our second precision drug candidate STP2, partnerships’ development and the in-licensing of potential additional compounds. In order to finance this growth, we are currently raising a series B of USD 65M, with target completion Q2-Q3 2022.”
About STALICLA
STALICLA SA is a Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders (NDDs), with a first application in autism spectrum disorder (ASD). STALICLA is on a unique mission to identify clinically actionable patient subgroups and develop tailored treatments for those most impaired by their symptoms. Its DEPI technology is the first platform specifically developed to enable precision medicine in complex NDDs. The platform integrates comprehensive metabolomics, whole-genome sequencing, RNA sequencing and its advanced HC match module to pair patient biological signatures with drug candidates. DEPI has reached clinical proof of concept with its first pipeline candidate, STP1. STALICLA is advancing collaborative alliances with strategic third-party pipelines and is rapidly scaling its platform and clinical development activity. For more information, please visit: https://stalicla.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005694/en/
Contact information
STALICLA
Lynn Durham, CEO and Founder
Lynn.Durham@Stalicla.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cannatrol, Creators of Breakthrough Postharvest Cannabis Technology, Receive Two European Patent Approvals25.4.2024 14:03:00 CEST | Press release
Cannatrol, the creators of the only total dry, cure and store system for the cannabis industry, announced today the approval of two European patents for its Vaportrol® Technology, protecting the proprietary technology throughout the European Union. “As the European cannabis industry grows, demand for precision drying, curing and storage technologies continues to expand,” said David Sandelman, co-founder, COO and CTO of Cannatrol. “Cannatrol’s proven environmental-control system ensures top-quality cannabis through a repeatable, consistent process, and it’s appropriate for any scale of cultivation, from large-scale greenhouse production to home growers.” Cannatrol’s patented postharvest technology is proven to increase yields and curing efficiency, and delivers on average 16% higher terpene retention when compared to traditional drying and curing methods, according to independent testing by The Cannabis Research Coalition. Throughout drying, curing and storage, the environment will stay
Visa Joins AWS Partner Network to Help Simplify Global Digital Payments25.4.2024 14:00:00 CEST | Press release
Visa (NYSE: V), a world leader in global digital payments, announced today it has joined the AWS Partner Network (APN), a global community that leverages AWS technologies, programs, expertise, and tools to build solutions and services for customers. Visa’s presence in the APN will help enable its partners and clients, including cloud-native fintechs, to access and integrate select Visa services more efficiently. Global Payments Simplified Visa is committed to making transactions faster, easier and more secure for all players in the payments ecosystem. Visa will make select payment services available in the AWS Marketplace, which has more than 300,000 global customers and thousands of software listings. By making its services available in AWS, Visa is meeting its clients where they are. One of the first services to be available is Visa Cross-Border Solutions, which assists in streamlining the process of sending and receiving money globally and holding multiple currencies. This strategic
Edgio Releases Client-Side Protection to Help Protect Users’ Data Against Malicious Scripts25.4.2024 14:00:00 CEST | Press release
Edgio, the platform of choice for security, speed and simplicity at the edge, today announced the release of its Client-Side Protection solution. Designed to monitor scripts and APIs on the browser-side to prevent malicious code from exfiltrating sensitive customer data, Edgio Client-Side Protection allows teams to gain full visibility on client-side vulnerabilities, achieve full control over all first- and third-party resources and maintain the latest compliance requirements. Payment Card Industry (PCI) Data Security Standard (DSS) v4.0 represents the latest global standards for protecting payment data against sophisticated cyber attacks. PCI DSS v4.0 reflects the latest needs of the payments industry as threats evolve, including damaging Magecart attacks, a type of digital credit card skimming. With Magecart skimmers spotted in over 2 million websites, organizations must prioritize proactively protecting customer data based on a comprehensive understanding of the scripts and external
Baseline Enrollment Completed for AMRA Medical and Linköping University’s Landmark Liver Disease Study25.4.2024 13:50:00 CEST | Press release
AMRA Medical, a health informatics and precision medicine company that is pioneering body composition research through gold-standard MRI-based analysis platforms, in collaboration with Linköping University, is pleased to announce the completion of baseline enrollment for the innovative ACCESS-ESLD (A Rapid, Non-invasive, Clinical Surveillance for CachExia, Sarcopenia, Portal HypertenSion, and Hepatocellular Carcinoma in End-Stage Liver Disease) study. The nationally-comprised study population includes 150 liver cirrhosis patients aged 18 and up, with no liver transplant history or contraindications to performing an MRI examination, enrolled from one of three Swedish liver care clinics located in Linköping, Eksjö, or Jönköping. Over a duration of 2 years, patients will be assessed every 6 months with a comprehensive clinical examination and a whole-body MRI examination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240425020
Geopolitical Unrest Generates an Onslaught of DDoS Attacks, According to the Latest NETSCOUT Threat Intelligence Report25.4.2024 12:05:00 CEST | Press release
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) today released findings from its 2H2023 DDoS Threat Intelligence Report that dissects trends and attack methodologies adversaries use against service providers, enterprises, and end-users. The information cited in the report is gathered from NETSCOUT’s unparalleled internet visibility at a global scale, collecting, analyzing, prioritizing, and disseminating data on DDoS attacks from 214 countries and territories, 456 vertical industries, and more than 13,000 Autonomous System Numbers (ASNs). Driven by tech-savvy and politically motivated hacktivist groups and an increase in DNS water torture attacks, NETSCOUT observed more than 7 million DDoS attacks in the second half of 2023, representing a 15% increase from the first half. Hacktivism Increases Ten-Fold DDoS (Distributed Denial-of-Service) hacktivism transcended geographic borders during the past year, exemplifying a shift in the global security landscape. Groups like NoName057(016) and Anonymous